Log in
Enquire now
‌

US Patent 9433800 Activatable particles, preparation and uses

Patent 9433800 was granted and assigned to Nanobiotix on September, 2016 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Nanobiotix
Nanobiotix
0
Current Assignee
Nanobiotix
Nanobiotix
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
94338000
Patent Inventor Names
Jeremy Balencie0
Jean-Francois Hochepied0
Paras Nath Prasad0
Laurent Levy0
Abdel Kader Boussaha0
Earl Jim Bergey0
Edouard Andre Panak0
Date of Patent
September 6, 2016
0
Patent Application Number
147075290
Date Filed
May 8, 2015
0
Patent Primary Examiner
‌
Michael G. Hartley
0
Patent abstract

The present invention relates to novel activatable particles which can be used in the health sector. The invention more particularly relates to composite particles which can generate free radicals or heat when excited by X rays, and to the uses thereof in health, particularly human. The inventive particles comprise an inorganic-based, and optionally organic-based, nucleus and can be activated in vivo, in order to label or alter cells, tissues or organs. The invention also relates to methods for the production of said particles, and to pharmaceutical or diagnostic compositions containing same.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9433800 Activatable particles, preparation and uses

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.